FDA approves Corlanor to treat heart failure
FDA has approved ivabradine (Corlanor, Amgen) to reduce hospitalization due to worsening heart failure. Corlanor is an antianginal agent approved for use in patients who have chronic heart failure caused by the lower-left part of the heart not contracting well.
FDA has approved ivabradine (Corlanor, Amgen) to reduce hospitalization due to worsening heart failure.
Heart failure is a condition affecting over 5 million people in the United States and is characterized by fatigue, shortness of breath and congestion related to inadequate tissue perfusion and fluid retention. Heart failure develops overtime as the heart loses its ability to pump due to myocardial injury. The leading causes of heart failure include cardiovascular diseases, such as coronary heart disease and hypertension.
Related: Study: Too many heart failure patients are treated with IV fluids
Corlanor is an antianginal agent approved for use in patients who have chronic heart failure caused by the lower-left part of the heart not contracting well. It is indicated for patients who have symptoms of heart failure that are stable, a normal heartbeat with a resting heart rate of at least 70 beats per minute and are also taking beta blockers at the highest dose they can tolerate.
Related: More FDA drug approvals
“Heart failure is a leading cause of death and disability in adults,” Norman Stockbridge, MD, Ph.D., director of the Division of Cardiovascular and Renal Products in FDA’s Center for Drug Evaluation and Research, said in a press release. “Corlanor is thought to work by decreasing heart rate and represents the first approved product in this drug class.”
The safety and efficacy of Corlanor were assessed in a clinical trial of 6,505 participants. Results showed that Corlanor reduced the time to first occurrence of hospitalization of hospitalization for worsening heart failure compared to an inactive drug. The most common side effects observed in the clinical trial included bradycardia, hypertension, atrial fibrillation, and temporary vision disturbances. Corlanor is to be dispensed along with a patient Medication Guide to provide information about its use and important safety important.
Read next: Telemonitoring of heart failure patients produces gains
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
